Cargando…

Non-valvular atrial fibrillation: impact of apixaban on patient outcomes

Atrial fibrillation is the most common arrhythmia worldwide, and carries a significantly increased risk of thromboembolic stroke. Initially, vitamin K antagonists were used as stroke prophylaxis; but more recently, a group of drugs known as novel oral anticoagulants have been developed. Apixaban bel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ioannou, Adam, Tsappa, Irene, Metaxa, Sofia, Missouris, Constantinos G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5680948/ https://www.ncbi.nlm.nih.gov/pubmed/29138609 http://dx.doi.org/10.2147/PROM.S117549

Ejemplares similares

Ventricular Fibrillation following Varicella Zoster Myocarditis
por: Ioannou, Adam, et al.
Publicado: (2017)

Anticoagulation for the prevention of stroke in non-valvular AF in general practice: room for improvement
por: Ioannou, Adam, et al.
Publicado: (2016)

Economic Evaluation of Apixaban for the Prevention of Stroke in Non-Valvular Atrial Fibrillation in the Netherlands
por: Stevanović, Jelena, et al.
Publicado: (2014)

Atrial Fibrillation is A Predictor of Drug-Related Bradycardia and Hospital Admission in Older Adults
por: Griffiths, Charlotte, et al.
Publicado: (2021)

Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia
por: Hersi, Ahmad S., et al.
Publicado: (2019)

Bleeding and Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation Treated with Apixaban or Rivaroxaban
por: ABDULLAH, Ahmad Salihin, et al.
Publicado: (2022)

Use, Persistence, Efficacy, and Safety of Apixaban in Patients with Non-Valvular Atrial Fibrillation in Unselected Patients in Germany. Results of the Prospective Apixaban in Atrial Fibrillation (APAF) Registry
por: Zeymer, Uwe, et al.
Publicado: (2020)

Comparative effectiveness of dabigatran, rivaroxaban, apixaban and warfarin in the management of patients with non-valvular atrial fibrillation
por: Pink, Joshua, et al.
Publicado: (2013)

A Systematic Literature Review on the Cost-Effectiveness of Apixaban for Stroke Prevention in Non-valvular Atrial Fibrillation
por: Pinyol, Carme, et al.
Publicado: (2016)

Dabigatran, rivaroxaban, and apixaban are superior to warfarin in Asian patients with non-valvular atrial fibrillation: An updated meta-analysis
por: Li, Wei-Jia, et al.
Publicado: (2021)

Do Apixaban Plasma Levels Relate to Bleeding? The Clinical Outcomes and Predictive Factors for Bleeding in Patients with Non-Valvular Atrial Fibrillation
por: Limcharoen, Sutee, et al.
Publicado: (2022)

Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study
por: Kjerpeseth, Lars J., et al.
Publicado: (2019)

Real-World Analysis of Potential Pharmacokinetic and Pharmacodynamic Drug Interactions with Apixaban in Patients with Non-Valvular Atrial Fibrillation
por: Badreldin, Hisham A, et al.
Publicado: (2020)

Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban
por: Tepper, Ping G., et al.
Publicado: (2018)

Newer Anticoagulants for Non-Valvular Atrial Fibrillation
por: Harburger, Joseph M., et al.
Publicado: (2012)

Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation
por: Ikeda, Kozue, et al.
Publicado: (2016)

Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK
por: Bowrin, Kevin, et al.
Publicado: (2020)

Comparison of the Efficacy and Safety of Apixaban and Warfarin in the Prevention of Stroke in Patients With Non-valvular Atrial Fibrillation: A Meta-Analysis
por: Memon, Rahat A, et al.
Publicado: (2022)

Metabolomic and Proteomic Analyses of Persistent Valvular Atrial Fibrillation and Non-Valvular Atrial Fibrillation
por: Hu, Bo, et al.
Publicado: (2021)

Safety and Efficacy of Apixaban in the Treatment of Atrial Fibrillation
por: Martin, Andrew, et al.
Publicado: (2012)

Cost-Effectiveness of Apixaban versus Warfarin in Chinese Patients with Non-Valvular Atrial Fibrillation: A Real-Life and Modelling Analyses
por: Li, Xue, et al.
Publicado: (2016)

Systematic review on left atrial appendage closure with the LAmbre device in patients with non-valvular atrial fibrillation
por: Ali, Muhammad, et al.
Publicado: (2020)

Clinical characteristics and 12-month outcomes of patients with valvular and non-valvular atrial fibrillation in Kenya
por: Temu, Tecla M., et al.
Publicado: (2017)

Prognostic implications of valvular heart disease in patients with non-valvular atrial fibrillation
por: Samaras, Athanasios, et al.
Publicado: (2021)

Adherence to rivaroxaban versus apixaban among patients with non-valvular atrial fibrillation: Analysis of overall population and subgroups of prior oral anticoagulant users
por: McHorney, Colleen A., et al.
Publicado: (2018)

Impact of age on thromboembolic events in patients with non‐valvular atrial fibrillation
por: Kim, Yun Gi, et al.
Publicado: (2019)

Practical Issues to Prevent Stroke Associated with Non-valvular Atrial Fibrillation
por: Kim, Chi Kyung, et al.
Publicado: (2013)

Cost-Effectiveness of Apixaban versus Other Direct Oral Anticoagulants and Warfarin in the Prevention of Thromboembolic Complications Among Finnish Patients with Non-Valvular Atrial Fibrillation
por: Hallinen, Taru, et al.
Publicado: (2021)

Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation
por: Bahit, M Cecilia, et al.
Publicado: (2017)

Impact of anticoagulation therapy on the cognitive decline and dementia in patients with non‐valvular atrial fibrillation (cognitive decline and dementia in patients with non‐valvular atrial fibrillation [CAF] trial)
por: Bunch, Thomas Jared, et al.
Publicado: (2022)

Novel oral Anticoagulants in Non-Valvular Atrial Fibrillation
por: da Silva, Rose M.F.L.
Publicado: (2014)

Novel Oral Anticoagulants in Atrial Fibrillation: Update on Apixaban
por: Mezue, Kenechukwu, et al.
Publicado: (2017)

Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation
por: Cirincione, Brenda, et al.
Publicado: (2018)

Apixaban enhances endogenous fibrinolysis in patients with atrial fibrillation
por: Spinthakis, Nikolaos, et al.
Publicado: (2019)

Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system
por: Villines, Todd C, et al.
Publicado: (2019)

Anticoagulant Prescribing for Non‐Valvular Atrial Fibrillation in the Veterans Health Administration
por: Rose, Adam J., et al.
Publicado: (2019)

Apixaban: An Update of the Evidence for Its Place in the Prevention of Stroke in Patients with Atrial Fibrillation
por: Seeger, Julia, et al.
Publicado: (2020)

Relationship between valvular structure and biochemical indices of non-valvular atrial fibrillation and senile degenerative valvular heart disease
por: Chen, Jian-Qin, et al.
Publicado: (2023)

Modification of the left atrial appendage and its role in stroke risk reduction with non-valvular atrial fibrillation
por: Rashid, Hashrul N., et al.
Publicado: (2020)

Causes of death of patients with non-valvular atrial fibrillation in Asians
por: Krittayaphong, Rungroj, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8k68je0rbrr4ensijh2lbf7ooj